We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
South San Francisco, CA-based Fluidigm Corporation , a leading player in the analysis of single cells and industrial application of genomics, recently unveiled a new high-throughput integrated fluidic circuit (HT IFC) to separate single cells during mRNA sequencing analysis.
Over the past six months, Fluidigm has traded below the Zacks categorized Medical Instruments sub-industry. The stock currently represents a negative return of 23.08%, much wider than the sub-industry’s decline of 2.6%. Additionally, Fluidigm lost 6.8% to close at $7.40 yesterday, following the dismal trends. Year to date, the company represented a loss of 31.5% while the S&P 500 rose 8.9%.
On the positive side, Fluidigm has compelling fundamentals in terms of revenues, multiplying at a CAGR of 27.3% over the last three years. Additionally, a long-term earnings growth rate of 25% instills investor confidence. Average volume of shares traded over the last three months was remarkable at approximately 259.2k. Currently, the stock has a market cap of $232.36 million.
Getting back to the development, HT IFC leverages on the company’s flagship Fluidigm C1 system, a leading automated solution for single-cell genomics. The introduction of the new medium-cell HT IFC paves way for greater single-cell capture and better workflow performance.
Per management, the latest development will provide researchers a strong platform to discover the wide range of cell populations (at single-cell resolution) and understand the role of rare cells in our lives.
Of the recent developments at the company, the distribution agreement with GenomOncology is worth mentioning. Per the terms of the deal, both the companies would co-market the ‘GO Clinical Workbench’, a knowledge-based software that provides decision support for oncology research programs.
For the coming quarters, Fluidigm is expected to develop small-cell HT IFC to provide high-throughput capabilities for neuronal and immune cell populations.
Our Take
Considering the opportunities for single cell analysis in the global markets, the recent development indicates possibilities of revival for the stock over the long term. On that note, a research report by Markets And Markets reveals that niche markets are expected to reach a worth of 3.35 billion by 2021, multiplying at a CAGR of 18.2%.
Zacks Rank & Key Picks
Currently, Fluidigm has a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader medical sector include Addus HomeCare Corporation (ADUS - Free Report) , LHC Group, Inc. and IDEXX Laboratories, Inc. (IDXX - Free Report) . Addus HomeCare and IDEXX Laboratories sport a Zacks Rank #1 (Strong Buy). Meanwhile, LHC Group carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Addus HomeCare has a long-term expected earnings growth rate of approximately 15%. Notably, the stock represents an impressive one-year return of 50%.
LHC Group has a long-term expected earnings growth rate of 15%. The company has returned almost 17.6% in the last three months.
IDEXX Laboratories has an expected earnings growth of almost 15%. The company posted a promising year-to-date return of almost 64%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 ""Strong Buy"" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 ""Strong Sells"" and other private research. See these stocks free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Fluidigm Unveils High-Throughput Integrated Fluidic Circuit
South San Francisco, CA-based Fluidigm Corporation , a leading player in the analysis of single cells and industrial application of genomics, recently unveiled a new high-throughput integrated fluidic circuit (HT IFC) to separate single cells during mRNA sequencing analysis.
Over the past six months, Fluidigm has traded below the Zacks categorized Medical Instruments sub-industry. The stock currently represents a negative return of 23.08%, much wider than the sub-industry’s decline of 2.6%. Additionally, Fluidigm lost 6.8% to close at $7.40 yesterday, following the dismal trends. Year to date, the company represented a loss of 31.5% while the S&P 500 rose 8.9%.
On the positive side, Fluidigm has compelling fundamentals in terms of revenues, multiplying at a CAGR of 27.3% over the last three years. Additionally, a long-term earnings growth rate of 25% instills investor confidence. Average volume of shares traded over the last three months was remarkable at approximately 259.2k. Currently, the stock has a market cap of $232.36 million.
Getting back to the development, HT IFC leverages on the company’s flagship Fluidigm C1 system, a leading automated solution for single-cell genomics. The introduction of the new medium-cell HT IFC paves way for greater single-cell capture and better workflow performance.
Per management, the latest development will provide researchers a strong platform to discover the wide range of cell populations (at single-cell resolution) and understand the role of rare cells in our lives.
Of the recent developments at the company, the distribution agreement with GenomOncology is worth mentioning. Per the terms of the deal, both the companies would co-market the ‘GO Clinical Workbench’, a knowledge-based software that provides decision support for oncology research programs.
FLUIDIGM CORP Price
FLUIDIGM CORP Price | FLUIDIGM CORP Quote
For the coming quarters, Fluidigm is expected to develop small-cell HT IFC to provide high-throughput capabilities for neuronal and immune cell populations.
Our Take
Considering the opportunities for single cell analysis in the global markets, the recent development indicates possibilities of revival for the stock over the long term. On that note, a research report by Markets And Markets reveals that niche markets are expected to reach a worth of 3.35 billion by 2021, multiplying at a CAGR of 18.2%.
Zacks Rank & Key Picks
Currently, Fluidigm has a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader medical sector include Addus HomeCare Corporation (ADUS - Free Report) , LHC Group, Inc. and IDEXX Laboratories, Inc. (IDXX - Free Report) . Addus HomeCare and IDEXX Laboratories sport a Zacks Rank #1 (Strong Buy). Meanwhile, LHC Group carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Addus HomeCare has a long-term expected earnings growth rate of approximately 15%. Notably, the stock represents an impressive one-year return of 50%.
LHC Group has a long-term expected earnings growth rate of 15%. The company has returned almost 17.6% in the last three months.
IDEXX Laboratories has an expected earnings growth of almost 15%. The company posted a promising year-to-date return of almost 64%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 ""Strong Buy"" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 ""Strong Sells"" and other private research. See these stocks free >>